World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
72395
World Ranking
12407
National Ranking
6351

Overview

Naiyer A. Rizvi is affiliated with Columbia University Medical Center in the United States and has an extensive publication record primarily in the field of Medicine, with a focus on Oncology and Pulmonary and Respiratory Medicine. Their research covers a broad spectrum of topics related to cancer immunotherapy, lung cancer treatments, and molecular biology.

Their recent published papers include:

  • Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial, 2021, The Lancet
  • Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial, 2020, The Lancet Oncology
  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer, 2020, JAMA Oncology
  • Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project, 2020, Journal for ImmunoTherapy of Cancer
  • Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response, 2020, Cancer Discovery

Naiyer A. Rizvi's frequently published venues include:

  • Cancer Research
  • Journal of Thoracic Oncology
  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Clinical Cancer Research

Collaboration forms an important part of their research output, working frequently with co-authors such as:

  • Brian S. Henick
  • Mark M. Awad
  • Justin F. Gainor
  • John V. Heymach
  • Catherine A. Shu

The main fields of study in their research are Medicine with a strong concentration on subfields including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Immunology
  • Molecular Biology

Their primary research topics focus on:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Lung Cancer Diagnosis and Treatment

Best Publications

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

    Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

    Diego Chowell;Luc G. T. Morris;Claud M. Grigg;Jeffrey K. Weber

  • Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Antoni Ribas;Omid Hamid;Adil Daud;F. Stephen Hodi

  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

    Matthew D. Hellmann;Naiyer A. Rizvi;Jonathan W. Goldman;Scott N. Gettinger

  • Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

    Vincent A. Miller;Mark G. Kris;Neelain Shah;Jyoti Patel

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

    Gregory J. Riely;William Pao;Duy Khanh Pham;Allan R. Li

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

    Matthew D. Hellmann;Margaret K. Callahan;Mark M. Awad;Emiliano Calvo

  • A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

    Marta Łuksza;Nadeem Riaz;Vladimir Makarov;Vinod P. Balachandran

  • Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

    Scott J. Antonia;Sarah B. Goldberg;Ani Sarkis Balmanoukian;Jamie E. Chaft

  • Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

    Ahmet Sezer;Saadettin Kilickap;Mahmut Gümüş;Igor Bondarenko

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

Frequent Co-Authors

Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Scott J. Antonia
Scott J. Antonia Duke University
Scott N. Gettinger
Scott N. Gettinger Yale University
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Solange Peters
Solange Peters University Hospital of Lausanne
William Pao
William Pao Roche (United States)
Leora Horn
Leora Horn Vanderbilt University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative routes to a healthcare career is becoming increasingly popular. Many students are looking for faster or more flexible pathways aside from traditional medical degrees. For example, online direct entry msn programs for non-nurses allow individuals with a non-nursing background to transition into advanced nursing roles in less time.

Those seeking a more accessible starting point may benefit from online adn programs for non nurses. These programs provide foundational nursing education, often with flexible schedules and less stringent admission requirements.

Not everyone pursuing a healthcare-related career wants to provide direct patient care. Administrative roles such as medical billing and coding are in high demand. There are numerous medical billing and coding schools online that offer accredited programs—many with financial aid options.

Prospective students worried about entrance exams can consider a lpn program no entrance exam. These options can help learners begin a healthcare career quickly and with less stress during the application process.

Best Scientists Citing Naiyer A. Rizvi

Trending Scientists

Recently Published Articles